EyePoint Pharmaceuticals reported $8.6 million and $20.4 million in fourth-quarter and 2019 revenues, respectively.
Here are four other things to know from the quarter:
1. ASCs drove quarterly purchasing, culminating in a 111 percent increase over the third quarter of 2019, with repeat customers representing 98 percent of fourth-quarter order volume.
2. Despite strong revenue growth, EyePoint posted a $10.4 million loss on the quarter and a $56.8 million loss on the year.
3. During the quarter, EyePoint appointed George Elston CFO and issued a public offering of 15 million shares of common stock at a price of $1.45 per share.
4. EyePoint believes its combination of cash and cash equivalents, along with the proceeds from the public offering and incoming cash, will fund the company's operations through 2021.